Status:
UNKNOWN
A Study of QL1706 in Subjects With Advanced Malignant Tumor
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Conditions:
Advanced Malignant Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is an open-label, multicenter, Phase 1, ascending dose escalation study of QL1706 in subjects with advanced malignant tumor. The study will be conducted in 2 parts. Part 1 of the study will be a ...
Detailed Description
The study was divided into screening/baseline, treatment and follow-up periods. Safety monitoring will be conducted throughout the study period. DLT will be determined 21 days (1 cycle) after the firs...
Eligibility Criteria
Inclusion
- Male or female subjects aged 18 years or older.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Life expectancy of ≥3 months.
- The functional level of important organs must meet the requirements before the first dose of study drug.
- Male and female patients able to have children must agree to use highly effective method of contraception throughout the study and for at least 180 days after last dose.Female subjects who are not pregnant or breastfeeding.
- Patients with pathological diagnosis of advanced/metastatic malignant tumor have progressed disease on standard therapy or for which no effective therapy is avalizble.
Exclusion
- Active or prior documented autoimmune disease. Subjects who have stable hypothyroidism with hormone replacement ,childhood atopy or asthma, vitiligo, alopecia, , or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
- Grade 3 or Grade 4 irAEs related to prior cancer immunotherapy.
- Known symptomatic brain metastases, leptomeningeal disease or spinal cord compression.
- Any medical condition likely to interfere with assessment of safety or efficacy of study treatment on decision of investigator. .
- Any condition requiring systemic treatment with corticosteroids or other immunosuppressive medications within 14 days before first dose of study drug. Corticosteroids for topical use, nasal spray, and inhaled steroids are allowed. Systemic corticosteroids for prophylaxis of contrast allergy are permitted.
- Systemic anti-cancer treatment. This includes radiotherapy ,small molecule targeted therapy\<2 weeks before the first dose of study drug, ≤4 weeks for chemotherapy，monoclonal antibody;≤8 weeks for cell-based therapy or anti-tumor vaccine.
- Major surgery within 28 days before the first dose of study drug and not recovered fully from any complications from surgery.
- Systemic infection requiring IV antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
- Subjects with the history of organ transplant or allogeneic hematopoietic stem cells transpalnt.
- Positive for Human immunodeficiency virus（HIV）or Hepatitis B ,active Hepatitis C.
- Active interstitial lung disease (ILD) or pneumonitis or a history of ILD.
Key Trial Info
Start Date :
March 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT04296994
Start Date
March 31 2020
End Date
December 1 2023
Last Update
April 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen Univeisity Cancer Center
Guangzhou, Guangdong, China